RT Journal Article
T1 Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19
A1 Gamarra Morales, Yenifer
A1 Herrera Quintana, Lourdes
A1 Molina López, Jorge
A1 Vázquez-Lorente, Héctor
A1 Machado Casas, Juan Francisco
A1 Castaño Pérez, José
A1 Pérez Villares, José Miguel
A1 Planells, Elena
AB Administering N-acetylcysteine (NAC) could counteract the effect of free radicals, improving the clinical evolution of patients admitted to the Intensive Care Unit (ICU). This study aimed to investigate the clinical and biochemical effects of administering NAC to critically ill patients with COVID-19. A randomized controlled clinical trial was conducted on ICU patients (n = 140) with COVID-19 and divided into two groups: patients treated with NAC (NAC-treated group) and patients without NAC treatment (control group). NAC was administered as a continuous infusion with a loading dose and a maintenance dose during the study period (from admission until the third day of ICU stay). NAC-treated patients showed higher PaO2/FiO2 (p ≤ 0.014) after 3 days in ICU than their control group counterparts. Moreover, C-reactive protein (p ≤ 0.001), D-dimer (p ≤ 0.042), and lactate dehydrogenase (p ≤ 0.001) levels decreased on the third day in NAC-treated patients. Glutathione concentrations decreased in both NAC-treated (p ≤ 0.004) and control (p ≤ 0.047) groups after 3 days in ICU; whereas glutathione peroxidase did not change during the ICU stay. The administration of NAC manages to improve the clinical and analytical response of seriously ill patients with COVID-19 compared to the control group. NAC is able to stop the decrease in glutathione concentrations.
PB MDPI
SN 2072-6643 (electrónico)
YR 2023
FD 2023-05
LK https://hdl.handle.net/10272/22435
UL https://hdl.handle.net/10272/22435
LA eng
NO Gamarra-Morales, Y., Herrera-Quintana, L., Molina-López, J., Vázquez-Lorente, H., Machado-Casas, J. F., Castaño-Pérez, J., Pérez-Villares, J. M., & Planells, E. (2023). Response to Intravenous N-Acetylcysteine Supplementation in Critically Ill Patients with COVID-19. In Nutrients (Vol. 15, Issue 9, p. 2235). MDPI AG. https://doi.org/10.3390/nu15092235
NO This research was funded by Project FIS PI10/1993 from the Spanish Carlos III HealthInstitute, the European Regional Development Fund (ERDF) “a way of making Europe” funded viathe Consejería de Universidad, Investigación e Innovación de la Junta de Andalucía [REF. A-CTS-708-UGR20]. Lourdes Herrera-Quintana [REF. FPU18/03702] and Héctor Vázquez-Lorente [REF.FPU18/03655] were awarded an FPU fellowship from the Spanish Ministry of Education.
DS Repositorio Institucional de la Universidad de Huelva
RD 13 jun 2026